How organizers of scientific meetings and journal editors could facilitate transfer of nanomedicine into the clinic

This opinion paper contains views on how organizers of scientific meetings and journal editors can facilitate transfer of new nanomedicine into the clinic. The need for interdisciplinary discussions at such meetings are emphasized, as well as the importance of learning from the regulatory authorities and large pharmaceutical companies about what is needed to bring new products into clinical use. The importance of improving the review process of translational studies published by the main nanomedical journals is pointed out as very important for bringing the field forward and to increase the level of scientific discussions in general.